Post-Hoc Exploratory Pooled Analysis of the Impact of IDP-126 Gel on QoL in Moderate-to-Severe Acne
Journal of Drugs in Dermatology · 2023
DOI: 10.36849/jdd.7812 ↗At a glance
Journal article in Journal of Drugs in Dermatology, 2023. Written by Linda Stein Gold and 8 co-authors. Major MEDLINE topics: Acne Vulgaris, Gels. Cited 2 times so far (Crossref).
Abstract (original language)
BACKGROUND: Acne has psychosocial effects on patient's quality of life (QoL). This post hoc exploratory analysis of pooled phase 3 data assessed the impact of investigational IDP-126 gel (for moderate to severe acne) on the Acne-Specific Quality of Life Questionnaire (Acne-QoL; exploratory endpoint in the trials).
Methods
A post hoc exploratory analysis using pooled data (N=309; age ≥13 years) was conducted to assess if 1) changes from baseline to week 12 in Acne-QoL domain scores significantly differ by treatment; 2) differences were clinically meaningful, and 3) relative importance of acne severity as measured by the Evaluator's Global Severity Score (EGSS) or lesion counts explains the changes in QoL (Acne-QoL).
Results
Acne-QoL domain scores significantly (P
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Gold, L. S., Harding, G., Borroto, D., Choudhury, S. P., Dutta, S. K., Lin, T., Kamleh, M., Joseph, G., & Dashputre, A. A. (2023). Post-Hoc Exploratory Pooled Analysis of the Impact of IDP-126 Gel on QoL in Moderate-to-Severe Acne. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7812
Vancouver
Gold LS, Harding G, Borroto D, Choudhury SP, Dutta SK, Lin T, et al. Post-Hoc Exploratory Pooled Analysis of the Impact of IDP-126 Gel on QoL in Moderate-to-Severe Acne. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.7812
BibTeX
@article{Gold2023,
author = {Gold, Linda Stein and Harding, Gale and Borroto, Danellys and Choudhury, Saswata Paul and Dutta, Sekhar Kumar and Lin, Tina and Kamleh, May and Joseph, George and Dashputre, Ankur A},
title = {Post-Hoc Exploratory Pooled Analysis of the Impact of IDP-126 Gel on QoL in Moderate-to-Severe Acne},
journal = {Journal of Drugs in Dermatology},
year = {2023},
doi = {10.36849/jdd.7812}
}
EUVIMED